Search
- Apr 2
Verve Therapeutics' CEO on today's gene editing clinical trial pause
Sek Kathiresan describes what Verve believes caused elevated liver enzymes and thrombocytopenia in a PCSK9 gene editing trial.
- Jan 7
Verve's Sek Kathiresan on 2023 progress and working to bring base editing for LDL lowering to market
Sek Kathiresan discusses Verve's first-in-human data, getting an IND cleared in the United States, and the company's partnership with Lilly.